<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424840</url>
  </required_header>
  <id_info>
    <org_study_id>UM200601</org_study_id>
    <nct_id>NCT00424840</nct_id>
  </id_info>
  <brief_title>Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy</brief_title>
  <official_title>Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy&#xD;
      in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this&#xD;
      combination in first line setting will be conducted in order to properly estimate the&#xD;
      efficacy and safety of this regimen. This will form the basis for future studies comparing&#xD;
      this combination to what is now considered standard regimen for first line therapy in&#xD;
      patients with NSCLC, carboplatin, paclitaxel and bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design and methodology The study will have two phases.&#xD;
&#xD;
      The phase I will use traditional dose escalation model (3-6 patient per dose level) to&#xD;
      determine the maximum tolerated dose (MTD).&#xD;
&#xD;
      *[In phase II, either level III or (MTD) will be used in the same every 21 day cycle to&#xD;
      evaluate the efficacy and safety of the regimen in first line treatment of advanced NSCLC]*&#xD;
      not conducted.&#xD;
&#xD;
      Treatments administered&#xD;
&#xD;
      In phase I, three dose levels of weekly bortezomib will be studied in conjunction with fixed&#xD;
      dose carboplatin and bevacizumab on a 21 day cycle to define the maximum tolerated dose&#xD;
      (MTD).&#xD;
&#xD;
      A maximum of six cycles will be administered. Patients with complete response, partial&#xD;
      response or stable disease after six cycles will be allowed to continue on single agent&#xD;
      bevacizumab every 3 weeks as maintenance therapy until disease progression.&#xD;
&#xD;
      If no dose limiting toxicity (DLT) is observed in 3 patients during the first cycle, the next&#xD;
      dose level will be accrued. If 1 DLT is observed, 3 additional patients will be accrued to&#xD;
      the dose level. If no additional DLTs are observed, the next dose level will be accrued.&#xD;
      However, if 2 or more DLTs are observed in a given dose level, MTD will be defined. MTD will&#xD;
      be defined as the dose below which ≥2 DLTs were observed.&#xD;
&#xD;
      The following three levels will be studied:&#xD;
&#xD;
      Level I (every 21 day cycle): D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1.3&#xD;
      mg/m2 D8 : bortezomib 1.3 mg/m2&#xD;
&#xD;
      Level II (every 21 day cycle): D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1.6&#xD;
      mg/m2 D8 : bortezomib 1.6 mg/m2&#xD;
&#xD;
      Level III(every 21 day cycle):D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1.8&#xD;
      mg/m2 D8 : bortezomib 1.8 mg/m2&#xD;
&#xD;
      If 2 or more DLT are observed in Level 1, level -1 will be accrued.&#xD;
&#xD;
      Level -1: (every 21 day cycle): D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1&#xD;
      mg/m2 D8: bortezomib 1 mg/m2&#xD;
&#xD;
      *[In phase II, either level III or the MTD dose level will be used in the same every 21 day&#xD;
      cycle to evaluate the efficacy and safety of the regimen in first line treatment of advanced&#xD;
      NSCLC.&#xD;
&#xD;
      Efficacy data collected&#xD;
&#xD;
      The following evaluations will be conducted to assess the efficacy of the combination:&#xD;
&#xD;
        -  response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria&#xD;
&#xD;
        -  disease free and overall survival, time to progress (TTP) and duration of response&#xD;
           Safety data collected&#xD;
&#xD;
      The following evaluations will be conducted to assess the safety of the combination&#xD;
      chemotherapy:&#xD;
&#xD;
      • toxicity based on National Cancer Institute-Common Terminology Criteria for Adverse Events&#xD;
      (NCI-CTCAE) version 3.0]* Not conducted&#xD;
&#xD;
      Statistical procedures&#xD;
&#xD;
      In phase I portion, 9-18 patients will be enrolled. The patients treated at recommended dose&#xD;
      level for phase II will also be eligible for response evaluation as part of phase II.&#xD;
&#xD;
      *[The primary objective of the phase II study is to estimate the efficacy and safety of the&#xD;
      combination therapy with carboplatin, bortezomib and bevacizumab as the first line therapy in&#xD;
      patients with advanced NSCLC. The primary endpoints are response rate and progression-free&#xD;
      survival (PFS).&#xD;
&#xD;
      (NOT CONDUCTED) In phase II portion, the optimal two-stage design for phase II clinical&#xD;
      trials described by Simon et al. will be utilized.&#xD;
&#xD;
      Overall survival, progression free survival and time to progression will be estimated using&#xD;
      Kaplan-Meier methods. Time to progression, progression free survival and survival will be&#xD;
      calculated from the date of study entry.]* (Phase II not conducted.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Require Dose Delay/Reduction in Dose of Bortezomibin the First Cycle</measure>
    <time_frame>up to 21 days for each dosing cycle</time_frame>
    <description>Dose limiting toxicity at Level 1,2 and 3: Number of subjects who required dose delay/reduction in dose of bortezomib in the first cycle of treatment. DLT defined by any of the following during first cycle: (1) GR4 neutropenia or thrombocytopenia, (2) Greater than GR3 non-hematological toxicity except alopecia or inadequately treated nausea or vomiting or (3) neurosensory toxicity of GR2 with pain or any neurotoxicity greater than GR2.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib 1.3 mg/m2</intervention_name>
    <description>Level I (every 21 day cycle, D8), 1.3 mg/m2:&#xD;
Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2&#xD;
Level II (every 21 day cycle):&#xD;
Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2&#xD;
Level III(every 21 day cycle):&#xD;
Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib 1.6 mg/m2</intervention_name>
    <description>Level II (every 21 day cycle, D8), 1.6 mg/m2</description>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib 1.8 mg/m2</intervention_name>
    <description>Level III (every 21 day cycle, D8) 1.8 mg/m2</description>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 6</intervention_name>
    <description>Carboplatin AUC6</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
    <other_name>Carboplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15 mg/kg</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>Taxotere 70 + G-CSF</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed SCLC (adeno- and large cell, anaplastic carcinoma and&#xD;
             broncho-alveolar-carcinoma). Patients with squamous-cell histology are eligible with&#xD;
             extra thoracic or peripheral lung lesions only.&#xD;
&#xD;
          -  Sputum cytology alone not acceptable evidence of cell type. Cytologic specimens&#xD;
             obtained by brushing, washings, or needle aspiration of defined lesions will be&#xD;
             acceptable. Mixed tumors will be categorized by the predominant cell type unless a&#xD;
             small cell anaplastic elements are present, in which case the patient is ineligible.&#xD;
&#xD;
          -  Stage III B because of pleural effusion or Stage IV disease&#xD;
&#xD;
          -  Measurable disease.&#xD;
&#xD;
          -  Age: 18 years or older&#xD;
&#xD;
          -  No history of thrombotic, hemorrhagic, or coagulopathy disorders&#xD;
&#xD;
          -  international normalized ratio (INR&lt;1.5) and a prothrombin time (PTT) no greater than&#xD;
             normal limits of normal within 1 week prior to registration. NB: subjects with lung&#xD;
             cancer placed on anticoagulant therapy for a thrombotic event are not eligible for&#xD;
             this study.&#xD;
&#xD;
          -  No gross hemoptysis (defined as bright red blood of ½ teaspoon or more)&#xD;
&#xD;
          -  No central nervous system (CNS) or brain metastasis&#xD;
&#xD;
          -  Laboratory Criteria (completed &lt;2 weeks before enrollment):&#xD;
&#xD;
               -  Hematologic: white blood cell (WBC) &gt; 3500/mm3 or absolute neutrophil count (ANC)&#xD;
                  &gt; 1500/mm3 and platelet count &gt; 100 000/ mm3;&#xD;
&#xD;
               -  Hepatic: Total bilirubin &lt; 1.5 mg/dl&#xD;
&#xD;
               -  Renal: Creatinine &lt; 1.5 mg/dl. or calculated&#xD;
&#xD;
               -  Creatinine clearance &gt; 45 ml/min (NB: Urine protein:creatinine ratio in exclusion&#xD;
                  criteria)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2&#xD;
&#xD;
          -  Be free of active infection.&#xD;
&#xD;
          -  Be available for active follow up.&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease.&#xD;
&#xD;
          -  Be disease free for &gt; 5 years if they had a prior second malignancy other than treated&#xD;
             basal cell carcinoma or squamous cell skin cancer, or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Female subject post-menopausal; surgically sterilized or willing to use an acceptable&#xD;
             method of birth control for the duration of the study. Male subject agrees to use an&#xD;
             acceptable method for contraception for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNS or brain metastasis&#xD;
&#xD;
          -  Patient has = or greater Grade 2 peripheral neuropathy within 14 days before&#xD;
             enrollment.&#xD;
&#xD;
          -  Known previous sensitivity reactions with boron, or mannitol,&#xD;
&#xD;
          -  Patients with known HIV positivity&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital&#xD;
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities. Any ECG abnormality at Screening&#xD;
             has to be documented by the investigator as not medically relevant.&#xD;
&#xD;
          -  Blood pressure of &gt;150/100 mmHG&#xD;
&#xD;
          -  History of myocardial infarction or stroke within 6 months&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to Day 0, anticipation of need for major surgical procedure during the course of&#xD;
             the study.&#xD;
&#xD;
          -  Minor surgical procedure such as fine needle aspirations or core biopsies within 7&#xD;
             days prior to day 0&#xD;
&#xD;
          -  Urine protein: Creatinine ratio &gt; 1.0 at screening&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess&#xD;
             within 6 months prior to Day 0&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Lung carcinoma or any histology in close proximity to a major vessel or cavitation&#xD;
&#xD;
          -  Female subject is pregnant or breast-feeding. Confirmation that the subject is not&#xD;
             pregnant. Pregnancy testing is not required for post-menopausal or surgically&#xD;
             sterilized women.&#xD;
&#xD;
          -  Patient has received other investigational drugs with 14 days before enrollment or is&#xD;
             expected to participate in an experiment drug study during this study treatment.&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of MassachusettsMedical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <reference>
    <citation>Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.</citation>
    <PMID>17167137</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <results_first_submitted>June 17, 2016</results_first_submitted>
  <results_first_submitted_qc>January 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2019</results_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>William Walsh</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>lung cancer, Carboplatin, bortezomib, Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Treatment q21 day cycle, maximum of 6 cycles. Patients with CR, PR, SD continued on single agent bevacizumab 15 mb/kg q 3 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1: 1.3 mg/m^2 Bortezomib</title>
          <description>Level 1 participants were given 1.3 mg/m^2 Bortezomib with Carboplatin AUC6, bevacizumab 15 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Dose Level II: 1.6 mg/m^2</title>
          <description>Participants were given1.6 mg/m^2 Bortezomib with Carboplatin AUC6, bevacizumab 15 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Dose Level III: 1.8 mg/m^2</title>
          <description>1.8 mg/m^2 Bortezomib with Carboplatin AUC6, bevacizumab 15 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: Dose Level 1, 2 and 3</title>
          <description>1.3 mg/m^2 Bortezomib&quot;, &quot;1.6 mg/m^2 Bortezomib&quot;, and &quot;1.8 mg/m^2 Bortezomib&#xD;
In phase I, three dose levels of weekly bortezomib will be studied in conjunction with fixed dose carboplatin and bevacizumab on a 21 day cycle to define the maximum tolerated dose (MTD).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="49" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Require Dose Delay/Reduction in Dose of Bortezomibin the First Cycle</title>
        <description>Dose limiting toxicity at Level 1,2 and 3: Number of subjects who required dose delay/reduction in dose of bortezomib in the first cycle of treatment. DLT defined by any of the following during first cycle: (1) GR4 neutropenia or thrombocytopenia, (2) Greater than GR3 non-hematological toxicity except alopecia or inadequately treated nausea or vomiting or (3) neurosensory toxicity of GR2 with pain or any neurotoxicity greater than GR2.</description>
        <time_frame>up to 21 days for each dosing cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Dose Level 1</title>
            <description>1.3 mg/m^2 Bortezomib</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Level II:</title>
            <description>1.6 mg/m^2 Bortezomib</description>
          </group>
          <group group_id="O3">
            <title>Phase I Dose Level III</title>
            <description>1.8 mg/m^2 Bortezomib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Require Dose Delay/Reduction in Dose of Bortezomibin the First Cycle</title>
          <description>Dose limiting toxicity at Level 1,2 and 3: Number of subjects who required dose delay/reduction in dose of bortezomib in the first cycle of treatment. DLT defined by any of the following during first cycle: (1) GR4 neutropenia or thrombocytopenia, (2) Greater than GR3 non-hematological toxicity except alopecia or inadequately treated nausea or vomiting or (3) neurosensory toxicity of GR2 with pain or any neurotoxicity greater than GR2.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>From date of first dose to date of death or up to 2 years, whichever came first Adverse event data by separate arms not available</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Bevacizumab, Carboplatin, Bortezomib</title>
          <description>In phase I, three dose levels of weekly bortezomib will be studied in conjunction with fixed dose carboplatin and bevacizumab on a 21 day cycle to define the maximum tolerated dose (MTD).&#xD;
Bevacizumab will be administered first followed by carboplatin followed by bortezomib</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed prematurely because of poor accrual prior to initiation of Phase 2, and is underpowered to definitely estimated the response rate and progression free survival.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. William Walsh</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>508-334-5539</phone>
      <email>William.Walsh@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

